Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 06, 2015 4:58 PM ET

Pharmaceuticals

Company Overview of Neurovance, Inc.

Company Overview

Neurovance, Inc. develops pharmaceutical preparations for the treatment of disorder of the central nervous system. The company was founded in 2011 and is based in Cambridge, Massachusetts.

43 Thorndike Street

Suite S1-3

Cambridge, MA 02141

United States

Founded in 2011

Phone:

617-758-0300

Key Executives for Neurovance, Inc.

Chief Executive Officer, President and Director
Chief Medical Officer
Vice President of Clinical Development
Compensation as of Fiscal Year 2014.

Neurovance, Inc. Key Developments

Neurovance, Inc. Announces Top-Line Results from a Human Abuse Liability Study in Recreational Stimulant Users

Neurovance, Inc. announced top-line results from a human abuse liability (HAL) study in recreational stimulant users. Centanafadine (CTN) sustained-release (SR) is a novel triple reuptake inhibitor being developed for the treatment of adults with ADHD and has shown favorable efficacy with good tolerability in a phase 2a patient study. Centanafadine works by modulating the activity of norepinephrine, dopamine and serotonin, three neurotransmitters known to be relevant in patients with ADHD. The results of the HAL study suggest that CTN has reduced abuse potential compared to the Schedule II stimulants which are commonly used for ADHD, though restricted due to risk of abuse and diversion. In the HAL study, treatment with CTN immediate release (IR) at high doses resulted in a markedly different profile than comparators (vs. Vyvanse or d-amphetamine or placebo) with acute onset of aversive effects in the majority of subjects including nausea, vomiting and dysphoria. Almost two hours after administration of CTN, test subjects reported liking at about two-thirds of the magnitude of amphetamines, a finding likely indicative of dopamine activity. However, unlike amphetamines that provided an immediate positive experience, subjects receiving CTN experienced negative effects before reaching this point. This early aversive profile of CTN is unique, inherent to the norepinephrine and serotonin pharmacology of the molecule, and is believed likely to deter abuse if the SR is misused. Full results of the HAL study were presented at the 53rd Annual Meeting of the American College of Neuropsychopharmacology in Phoenix on December 10th. The HAL study was a five-arm crossover study designed to evaluate the abuse liability potential for CTN IR among subjects known to use recreational stimulants. Single doses of 400 or 800 mg IR were tested alongside Schedule II comparators d-amphetamine or lisdexamfetamine (Vyvanse), or placebo. The findings showed that CTN IR, at a dose sufficient to elicit a measurable reward, would also result in negative effects. For example, subjects said they would significantly prefer to take d-amphetamine as compared to CTN 800 mg.

Neurovance Appoints Brigitte Robertson as VP of Clinical Development

Neurovance announced that Brigitte Robertson, MD, has been appointed Vice President of Clinical Development. The company said that Dr. Robertson brings the Company nearly 20 years of expertise as a board certified adult, child and adolescent psychiatrist specializing in attention deficit hyperactivity disorder (ADHD), with over 15 years of clinical development experience focused on ADHD treatments. Most recently, Dr. Robertson served as Global Development Strategy Team Lead, Senior Director at Shire Pharmaceuticals.

Neurovance Appoints Brigitte Robertson as Vice President, Clinical Development

Neurovance, Inc. announced that Brigitte Robertson, MD, has been appointed as Vice President of Clinical Development. Most recently, Dr. Robertson served as Global Development Strategy Team Lead, Senior Director at Shire Pharmaceuticals, where she led multiple cross-functional global development teams and was accountable for the development strategy and execution for several development programs in ADHD involving Intuniv, SPD465 and Vyvanse, the leading ADHD franchise worldwide. Dr. Robertson will contribute to the development of Neurovance's centanafadine SR (formerly EB-1020 SR), a non-stimulant being developed for the treatment of adults with ADHD. She joins Neurovance with significant clinical and industry experience including senior roles at CCP Children's Hospital in San Diego, and Glaxo and Sepracor.

Similar Private Companies By Industry

Company Name Region
Active Organics Inc. United States
Chirologix Pharmaceuticals United States
Organon USA, Inc. United States
SanBio, Inc. United States
Bracco U.S.A., Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Neurovance, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.